AccuStem Sciences, Inc. and EmeritusDX Announce Joint Product
Development Agreement and Strategic Partnership
London, UK and Phoenix, AZ
-- July 17, 2023 -- InvestorsHub NewsWire -- AccuStem
Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company
dedicated to improving outcomes for patients with cancer, and
EmeritusDX, a rapidly growing cancer diagnostics and information
company, today announced the execution of an agreement wherein both
companies will jointly manage scientific operations and R&D for
AccuStem's product portfolio.
Initial plans as part of
the collaboration will be to immediately focus on furthering the
validation of AccuStem's core offering, StemPrintER, for patients
with breast cancer. The proprietary 20-gene test stratifies
patients according to their recurrence risk and is intended to
measure the "stemness" of tumors, or how much they behave like stem
cells, which may indicate the likelihood of cancer progression and
response to standard treatment modalities. While StemPrintER has
been shown to outperform the current market leader for risk of
recurrence testing in patients with breast cancer, OncotypeDX
(Exact Sciences, NASDAQ: EXAS), this alliance will further
establish the utility of the assay in addressing unanswered
clinical questions such as identifying which surgical intervention
will improve outcomes.
"We
are excited about the opportunity to partner with EmeritusDX," said
Wendy Blosser, CEO of AccuStem. "Their expertise in the diagnostic
space in combination with their proven track record of success is
exactly what AccuStem has been looking for in a lab partner to take
StemPrintER through the validation and reimbursement process for
breast cancer and other indications."
EmeritusDX, a
pioneering cancer diagnostics and information company, continues
its commitment to transforming cancer care through personalized
medicine. Operating from their state-of-the-art facilities in
California and Pennsylvania, EmeritusDX will leverage their
top-tier molecular laboratories and a seasoned research and
development team to validate the StemPrintER assay. This crucial
collaboration with AccuStem is aimed at showcasing the clinical
utility of the test while advancing precision medicine. By joining
forces, EmeritusDX and AccuStem strive to provide healthcare
providers with actionable insights that drive improved patient
outcomes, empowering them with the tools they need to make informed
decisions in the fight against cancer.
"AccuStem's proprietary
technology evaluating tumor stemness offers endless opportunities
for healthcare providers to address a variety of clinically unmet
needs for cancer patients," said Robert Embree, CEO of EmeritusDX.
"StemPrintER complements our existing product pipeline by
addressing additional questions along the patient care continuum
beyond what we are currently doing today."
The leadership teams
believe this strategic partnership will position StemPrintER for an
expeditious launch in breast cancer while bolstering their research
and development efforts to expand its indication to other tumor
types in the future.
About AccuStem
AccuStem is a clinical stage diagnostics company
dedicated to optimizing outcomes and quality of life for all
patients with cancer. We plan to drive innovation in healthcare by
offering proprietary molecular testing that addresses unmet
clinical needs from cancer screening through treatment and
monitoring. By interrogating novel disease pathways, such as tumor
"stemness," we believe our tools will help care teams better
understand the biology of each patient's cancer, leading to more
informed decision making. For more information, please
visit www.accustem.com.
About EmeritusDX
EmeritusDX is a cancer diagnostic and information
company. Our expertise is in delivering actionable clinical
information. Within our world-class laboratory, we perform testing
that guides the diagnosis and treatment of cancer patients. Our
partners include hospital and private pathology laboratories,
biotechnology companies, academic institutions, contract research
and pharmaceutical development organizations, and more. We
understand the dependency on our accurate and timely results and
our commitment to excellence in this regard is
unwavering.
Forward-Looking Statements
This press release contains "forward-looking statements"
Forward-looking statements reflect our current view about future
events. When used in this press release, the words "anticipate,"
"believe," "estimate," "expect," "future," "intend," "plan," or the
negative of these terms and similar expressions, as they relate to
us or our management, identify forward-looking statements. Such
statements, include, but are not limited to, statements contained
in this press release relating to our business strategy, our future
operating results and liquidity and capital resources outlook.
Forward-looking statements are based on our current expectations
and assumptions regarding our business, the economy and other
future conditions. Because forward–looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict. Our actual
results may differ materially from those contemplated by the
forward-looking statements. They are neither statements of
historical fact nor guarantees of assurance of future performance.
We caution you therefore against relying on any of these
forward-looking statements. Important factors that could cause
actual results to differ materially from those in the
forward-looking statements include, without limitation, our ability
to raise capital to fund continuing operations; our ability to
protect our intellectual property rights; the impact of any
infringement actions or other litigation brought against us;
competition from other providers and products; our ability to
develop and commercialize products and services; changes in
government regulation; our ability to complete capital raising
transactions; and other factors relating to our industry, our
operations and results of operations. Actual results may differ
significantly from those anticipated, believed, estimated,
expected, intended or planned.
Factors or events that could cause our actual results to differ may
emerge from time to time, and it is not possible for us to predict
all of them. We cannot guarantee future results, levels of
activity, performance or achievements. AccuStem Sciences, Inc.
assumes no obligation to update any forward-looking statements in
order to reflect any event or circumstance that may arise after the
date of this release.
Media
Contact:
Joe Flanagan
Email: joe@accustem.com
Investor
Contact:
Wendy Blosser, CEO
Email: investors@accustem.com